{"created":"2023-05-15T14:44:50.880696+00:00","id":61300,"links":{},"metadata":{"_buckets":{"deposit":"bc017c22-0e19-458b-a9cd-17ae70442bbe"},"_deposit":{"created_by":1,"id":"61300","owners":[1],"pid":{"revision_id":0,"type":"depid","value":"61300"},"status":"published"},"_oai":{"id":"oai:repo.qst.go.jp:00061300","sets":["10:29"]},"author_link":["606802","606801"],"item_10005_date_7":{"attribute_name":"発表年月日","attribute_value_mlt":[{"subitem_date_issued_datetime":"2006-02-26","subitem_date_issued_type":"Issued"}]},"item_10005_description_5":{"attribute_name":"抄録","attribute_value_mlt":[{"subitem_description":"In 1994, a clinical study on carbon-ion therapy was begun at NIRS using HIMAC (Heavy-Ion Medical Accelerator in Chiba), which was then the world痴 only heavy ion accelerator complex dedicated to medical use in a hospital environment. Among several types of ion species, carbon ions were chosen for cancer therapy because they had the most optimal properties in terms of biologically effective dose-localization in the body. The purpose of the clinical study was to investigate the efficacy of carbon ions against a variety of tumors as well as to develop effective techniques for delivering the efficient dose to the tumor. The RBE of carbon ions was estimated to be 2.0〜3.0 along the SOBP for acute skin reactions. As of July 2005, a total of 2.371 patients were entered in Phase I/II or Phase II trials and were analyzed for toxicity and tumor response. The results have shown that carbon ion therapy has the potential ability to provide a sufficient dose to the tumor with acceptable morbidity in the surrounding normal tissues. Tumors that appear to respond favorably to carbon ions include locally advanced tumors and those with histologically non-squamous cell type of tumors such as adenocarcinoma, adenoid cystic carcinoma, malignant melanoma, hepatoma, and bone and soft tissue sarcoma. By using biological and physical properties of high-LET radiations, the efficacy of treatment regimen with small fractions in short treatment times has been confirmed for almost all type of tumors in carbon ion therapy.","subitem_description_type":"Abstract"}]},"item_10005_description_6":{"attribute_name":"会議概要（会議名, 開催地, 会期, 主催者等）","attribute_value_mlt":[{"subitem_description":"NIRS-MedAustron Joint Symposium on Carbon Ion Therapy in Cancer","subitem_description_type":"Other"}]},"item_access_right":{"attribute_name":"アクセス権","attribute_value_mlt":[{"subitem_access_right":"metadata only access","subitem_access_right_uri":"http://purl.org/coar/access_right/c_14cb"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"Tsujii, Hirohiko"}],"nameIdentifiers":[{"nameIdentifier":"606801","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"辻井 博彦","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"606802","nameIdentifierScheme":"WEKO"}]}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"eng"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"conference object","resourceuri":"http://purl.org/coar/resource_type/c_c94f"}]},"item_title":"Overview of the Carbon Ion Therapy with HIMAC in Chiba","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"Overview of the Carbon Ion Therapy with HIMAC in Chiba"}]},"item_type_id":"10005","owner":"1","path":["29"],"pubdate":{"attribute_name":"公開日","attribute_value":"2006-02-28"},"publish_date":"2006-02-28","publish_status":"0","recid":"61300","relation_version_is_last":true,"title":["Overview of the Carbon Ion Therapy with HIMAC in Chiba"],"weko_creator_id":"1","weko_shared_id":-1},"updated":"2023-05-15T21:43:59.737481+00:00"}